A classic aging intervention stops working when mitochondria are damaged
Suppressing IGF-1, a growth signaling pathway that has been studied for decades as a key to longer life, barely extends lifespan in mice with heavily damaged mitochondria.
IGF-1 signaling is arguably the best-studied mechanism in all of aging biology. The discovery that worms, flies, and mice live longer when this growth-hormone-related pathway is dialed down dates back to the 1990s. It became a cornerstone of the field — and a major inspiration for calorie restriction research, since fasting partially dampens this same pathway. New results now cast serious doubt on how universal that effect really is.
Researchers worked with so-called mitochondrial mutator mice — animals genetically engineered to accumulate errors in their mitochondrial DNA at an accelerated rate. Mitochondria are the cell’s power generators; faults in their genetic code build up throughout life and are considered one of the primary engines of biological aging. In these mice, that process is dramatically sped up, making them a widely used model for studying mitochondria-driven aging.
Two pathways, one bottleneck
The working hypothesis was that suppressing IGF-1 signaling — either genetically or pharmacologically — would extend the lifespan of these mice, as it reliably does in healthy controls. That hypothesis did not hold up. In mice whose mitochondria were already severely compromised, the intervention had little effect on how long they lived. The body appeared unable to convert reduced growth signaling into extended lifespan when its energy production was fundamentally impaired.
What this suggests is that IGF-1 signaling and mitochondrial health are not independent variables in the aging equation — they are deeply intertwined. Dialing down growth signals may only work when the cellular energy infrastructure is intact enough to benefit from reduced growth drive. When the foundation is already broken, adjusting the signal does not help.
This has implications for how aging interventions are evaluated. Much of the research on calorie restriction and IGF-1-suppressing compounds has been conducted in relatively healthy young laboratory animals. Whether those findings hold in older animals carrying more background damage — or in humans, who typically accumulate far more mitochondrial mutations than young lab mice — is a question this study answers in the negative, at least under one set of conditions.
A warning for drug development
For pharmaceutical development, this is a meaningful caution. Drugs that suppress IGF-1 signaling are actively being investigated for their links to cancer and metabolic disease. The hypothesis that they might simultaneously serve as aging interventions is not supported here — at least not in the context of significant mitochondrial dysfunction.
The mitochondrial mutator mouse is an extreme model, and humans are not mice. But the core insight is uncomfortable: two of the most studied aging mechanisms do not appear to simply add up. Whether a universal brake on aging exists — and whether it could work across the full spectrum of biological damage — remains very much an open question.